DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Vergote I et al.
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated
liposomal doxorubicin or topotecan as third-line therapy in patients with
platinum-refractory or -resistant ovarian cancer.
2009. (1879-0852 [Electronic])
We do not assume any responsibility for the contents of the web pages of other providers.